➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim

Last Updated: June 18, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for TAK-981

Email this page to a colleague

« Back to Dashboard

What is the drug development status for TAK-981?

TAK-981 is an investigational drug.

There have been 348 clinical trials for TAK-981. The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2018.

The most common disease conditions in clinical trials are Diabetes Mellitus, Hypertension, and Diabetes Mellitus, Type 2. The leading clinical trial sponsors are Takeda, Millennium Pharmaceuticals, Inc., and National Cancer Institute (NCI).

There is one US patent protecting this investigational drug and thirty-nine international patents.

Recent Clinical Trials for TAK-981
A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)Janssen Pharmaceutical K.K.Phase 3
A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of CancersTakedaPhase 1
A Study of TAK-994 in Adults With NarcolepsyTakedaPhase 2

See all TAK-981 clinical trials

Clinical Trial Summary for TAK-981

Top disease conditions for TAK-981
Top clinical trial sponsors for TAK-981

See all TAK-981 clinical trials

International Patents for TAK-981

Drugname Country Document Number Estimated Expiration Related US Patent
TAK-981 Argentina AR101038 2034-07-01   Try Before You Buy
TAK-981 Australia AU2015284135 2034-07-01   Try Before You Buy
TAK-981 Canada CA2953132 2034-07-01   Try Before You Buy
TAK-981 Chile CL2016003398 2034-07-01   Try Before You Buy
TAK-981 China CN106999479 2034-07-01   Try Before You Buy
TAK-981 Costa Rica CR20170021 2034-07-01   Try Before You Buy
TAK-981 Denmark DK3164130 2034-07-01   Try Before You Buy
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.